Sudeep Pharma Limited · NSE:SUDEEPPHRM
Sudeep Pharma — Q3 FY26 Earnings Presentation
37 slides from Sudeep Pharma's earnings presentation, Feb 7, 2026
Slide 1: Exchange Submission Letter: Q3FY26 Result Presentation
Date: 07th February, 2026 To, National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Q3FY26 - Result Presentation Ref:
Slide 2: Sudeep Pharma Limited Investor Presentation February 2026
Sudeep Pharma Limited Investor Presentation February 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sudeep Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Q3 & 9MFY26 Performance Highlights
Q3 & 9MFY26 Performance Highlights
Slide 5: MD's Message
MD’s Message “We are pleased to report a strong performance in Q3 FY26, with revenue growth of 52% YoY and EBITDA and PAT growth of 60% and 66% YoY, respectively, driven by healthy demand across both business segments. The quarter was particularly significant, marked by multiple strategic developmen
Slide 6: Q3 & 9MFY26 Performance Highlights
Q3 & 9MFY26 Performance Highlights Total Income EBITDA & Margin % PAT & Margin % Rs. Cr. Rs. Cr. Rs. Cr. 35.4% 37.3% 39.1% 37.6% 24.3% 26.6% 27.0% 26.1% +38% +33% +33% 482.1 181.5 125.7 350.0 +52% 136.7 94.5 +60% +66% 179.2 66.8 118.0 47.7 41.7 28.7 Q3FY25 Q3FY26* 9MFY25 9MFY26* Q3FY25 Q3FY26* 9MFY2
Slide 7: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q3FY26* Q3FY25 YoY 9MFY26* 9MFY25 YoY FY25 Revenue from Operations 172.3 115.5 459.9 344.5 502.0 Other Income 6.8 2.4 22.2 5.6 9.3 Total Income 179.2 118.0 52% 482.1 350.0 38% 511.3 Cost of materials consumed 60.2 37.9 163.5 105.0 164.8 Empl
Slide 8: Battery Materials - Ground Breaking Ceremony of Land in Dahej, Gujarat
Battery Materials - Ground Breaking Ceremony of Land in Dahej, Gujarat Successfully conducted the groundbreaking ceremony for Battery Materials Plant at Dahej on January 23, 2026. Setting up plant at Dahej, Gujarat • Project cost: Appx. Rs 300 crores • Expect completion by early CY27 • Mode of Finan
Slide 9: Capacity Expansion & Strategic Validation
Capacity Expansion & Strategic Validation Strategic Positioning: Emerging as a premier reliable non-Chinese supplier for battery-grade iron phosphate PCAM. Manufacturing Scale: Global Presence in Dominant Battery Markets Phase 1: 34 26 Customers across South Korea, Japan, Indonesia, Europe, USA, & A
Slide 10: Company Overview
p Pharma Limited s Sudee Company Overview
Slide 11: Sudeep Pharma at a Glance
Sudeep Pharma at a Glance Founded in 1989, 3+ decades of experience in 35 Years of Expertise in vitamins & mineral chemistries* 5 Manufacturing Sites ^ Specialty Chemistries Metric Tones (“MT”) Fortune 500 Companies1 Leading player in the Excipients & 14 as customers ~1,23,000 + Annual Manufacturing
Slide 12: Our Journey from Pharma Excipients to Specialty Ingredients Manufacturer
Our Journey from Pharma Excipients to Specialty Ingredients Manufacturer 2025 2024 2021–2023 2015–2022 Strategic 1989 Acquisitions & Diversification & IPO Readiness Ownership Innovation and Consolidation Global Portfolio Foundation & Partnerships & Expansion Early Market Entry Operations 2024 2025 2
Slide 13: Corporate Structure
Corporate Structure Sudeep Pharma Limited (Holding) Sudeep Nutrition Private Ltd. Sudeep Pharma USA Inc. Sudeep Pharma B.V. Sudeep Advanced Materials (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) 85% Ownership 12
Slide 14: One of the World's Leading and Trusted Manufacturer
One of the World’s Leading and Trusted Manufacturer The Start At Present 2020 2021 2023 2024 2025 Ireland Manufacturing 5 Site¹ Manufacturing Sites^ Europe Sales Office – The HQ - Vadodara, Netherlands² Gujarat³ 100+ Products 4 Manufacturing USA Sales Office - New Sites, India ⁴ Jersey² Mumbai Offic
Slide 15: Strengths - Core Competencies and USP's
Strengths - Core Competencies and USP’s Innovation Engineered Through Proprietary Technologies Leadership in High Barrier Industry, Diversified Product Portfolio 6 indigenously developed technologies 100+ Products across different verticals Encapsulation Spray Drying Granulation Liposomal Trituratio
Slide 16: Key Value Propositions
Key Value Propositions 1. Market Leadership with 6. Distinguished global Diversified Product customer base with long Portfolio standing relationships with Key Customers 2. High Entry Barriers 7. Proven Credentials and Leading Accolades Key 3. Well-Equipped & Value 8. Experienced Board and Regulatory
Slide 17: 1. Market Leadership with Diversified Product Portfolio
1. Market Leadership with Diversified Product Portfolio Delivering Products that Matter Pharmaceutical, Food & Nutrition Speciality Ingredients Battery Materials Mineral Micro-nutrient Liposomal Fillers Ingredients Battery-Grade Iron Phosphate* Fortificants Premixes pCAM for LFP (Lithium Iron Phosph
Slide 18: 2. High Entry Barriers
2. High Entry Barriers Cost Split of a Tablet Composition split of a Tablet ~5% Excipients ~95% API ~95% Excipients ~5% API Low Cost but High Functionality Disintegration & Tablet Performance^ Stability of Tablet^ Dissolution^ Product Range Tailored to Meet the Precise Needs of Customers in a High B
Slide 19: 3. Well-Equipped & Regulatory Compliant Manufacturing Facilities
3. Well-Equipped & Regulatory Compliant Manufacturing Facilities Unit I – Nandesari Unit II – Nandesari 12 Set Up 1989 Set Up 2011 Production Lines Calcium Carbonate - Powder, Tricalcium Phosphate, Dicalcium Products Oxides, Carbonates, Sulphates Products Phosphate, Iron Phosphate, Magnesium Stearat
Slide 20: 4. Proprietary Technologies
4. Proprietary Technologies Encapsulation Spray Drying Granulation Blending Liposomal Preparation Trituration Expertise In: Extending Product Shelf-life Target, Controlled and Sustained Release Address Taste and Odor Challenges Particle Engineering Enhance Ingredient Bio-Availability Improved Produc
Slide 21: 5. Strong Research & Development Capabilities
5. Strong Research & Development Capabilities 420 R&D Projects 127 Products Commercialized R&D Expenses (% of Revenue from Operations) 1.96% 1.71% 41 R&D Personnel 6 Proprietary Technologies 1.17% 0.91% R&D Initiatives Assist in^ : FY23 FY24 FY25 9MFY26 • Extending Product Shelf-Life & Vitality • En
Slide 22: 6. Distinguished global customer base with long standing relationships
6. Distinguished global customer base with long standing relationships with Key Customers ^ 84.38% 14 8% 1,100+ Single Largest Of revenue* as repeat Global Fortune 500 Customers served^ Customer business companies as customers^ ^ ^ 25% 36% 40+ 7.08 Years ~100 Countries Top 10 Blue-chip multinational
Slide 23: 7. Proven Credentials and Leading Accolades
7. Proven Credentials and Leading Accolades Key Awards Key Certifications FRK Manufacturing Customer Centric Excellence Business Partner Award Award By Millers for By Abbott Nutrition Suppliers Excellence in Summit 2023 Innovative Award Ingredients Manufacturing By Herbalife By Nutrition ASSOCHAM Gl
Slide 24: 8. Experienced Board and Senior Management Team
8. Experienced Board and Senior Management Team Promoters & Directors Board Members Mr. Ajay Kandelkar- Director of Operations Dairy technology from Dr. Panjabrao Deshmukh KV 23 years of experience in production & operations Past Association - Drytech, Taiyo-Kagaku Independent Director Mr. Samaresh
Slide 25: 9. Healthy Improvement in Performance with Disciplined Balance Sheet
9. Healthy Improvement in Performance with Disciplined Balance Sheet Total Income EBITDA & Margin % Rs. Cr. Rs. Cr. 22.5% 40.3% 39.0% 37.6% +8% 511.3 465.4 482.1 438.3 +42% 187.8 199.3 181.5 98.6 FY23 FY24 FY25 9MFY26* FY23 FY24 FY25 9MFY26* PAT & Margin % Net Debt & Net Debt / Equity (x) Rs. Cr. Rs
Slide 26: 10. Backed by Healthy Growth in End User Industries
10. Backed by Healthy Growth in End User Industries Battery Speciality Ingredients Pharmaceutical Excipients Chemicals Food Nutritional Encapsulated Micronutrient Granulated Global India Global Market Ingredients Ingredients Ingredients Ingredients Ingredients Excipients Excipients Market Size USD 8
Slide 27: Growth Levers
n ro o > ® al ra s S ) = 10)
Slide 28: Key Capacity Expansion
Key Capacity Expansion Capacity Visibility (in MT)* FY25 Key Segments FY26e FY27e FY28e FY29e FY30e Existing 1) Pharma, Food & Nutrition 35,000 86,000 86,200 86,200 86,200 86,200 - Greenfield Project Addition 51,200 2) Speciality Ingredients 30,000 37,500 37,500 37,500 37,500 37,500 - NSS Capacity A
Slide 29: 1. Organic Growth – Upcoming Greenfield Expansion
1. Organic Growth – Upcoming Greenfield Expansion Upcoming Greenfield at Nandesari, Gujarat Location Total Capex Capacity Nandesari GIDC, Gujarat ~ 150 Crores INR 51,200 MT Annually Focused Segment Mode of Financing Expected Commissioning By Pharmaceutical Excipients, Actives and Internal Accruals Q
Slide 30: 2. Organic Growth – Leveraging Mineral Chemistry Expertise for Battery Materials
2. Organic Growth – Leveraging Mineral Chemistry Expertise for Battery Materials Key Pillar Our Advantage Leveraging Decade of expertise in Iron Phosphate FEOC-Compliant Supply Fully aligned with FEOC compliance norms, helping customers meet regulations Chain under the US IRA & EU Critical Raw Mater
Slide 31: 3. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition
3. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition Integrate Recently Acquired Entities & Continue Evaluating Inorganic Growth Opportunities Acquired 85.00% Engaged in business of manufacturing of vitamin & mineral blends in form May 2025 of dry blends, water soluble blends, oil sol
Slide 32: Historical Financial Statements
Historical Financial Statements
Slide 33: Historical Profit & Loss Statement
Historical Profit & Loss Statement Particulars (Rs. Crs) FY25 FY24 FY23 Revenue from Operations 502.0 459.3 428.7 Other Income 9.3 6.1 9.5 Total Income 511.3 465.4 438.3 Cost of materials consumed 164.8 165.3 182.5 Employee Expenses 38.3 29.4 66.1 Other Expenses 108.9 82.9 91.1 EBITDA 199.3 187.8 98
Slide 34: Historical Balance Sheet Statement
Historical Balance Sheet Statement Assets (Rs. Crs) Mar-25 Mar-24 Mar-23 Equity & Liabilities (Rs. Crs) Mar-25 Mar-24 Mar-23 Non - Current Assets 293.1 238.5 190.1 Total Equity 493.1 356.0 223.3 Property, plant and equipment 177.1 167.0 149.4 Equity share capital 9.7 1.4 1.4 Capital work-in-progress
Slide 35: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (Rs. Crs) Mar-25 Mar-24 Mar-23 Net Profit Before Tax 182.8 174.8 86.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 15.5 13.5 17.9 Operating profit before working capital changes 198.3 188.3 103.9 Changes in working capital -109.0 -
Slide 36: Utilization of Net Proceeds
Utilization of Net Proceeds Particulars Original Amount Utilized in 9MFY26 Amount Un-utilized Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I 75.8 - 75.8 General Corporate Purposes 12.5 12.5 - Total 88.3 12.5 75.8 35
Slide 37: Thank You!
Thank You! Company Details: Investor Relations Advisor : Strategic Growth Advisors Pvt. Ltd. Sudeep Pharma Ltd. CIN - U74140MH2010PTC204285 CIN – L24231GJ1989PLC013141 Mr. Shrikant Sangani / Ms. Shaily Patwa Ms. Dimple Mehta – Company Secretary Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net